Twelve studies provided the association between CD73 and overall survival, including two studies for ovarian cancer, one study for renal cancer, five studies for gastrointestinal cancer, three studies for breast cancer, and one study about prostate cancer. This evidence concerns the gene NT5E and prostate cancer.